trending Market Intelligence /marketintelligence/en/news-insights/trending/NPBHG3YMivtOXHcZeBuAaQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Axim Biotechnologies to acquire oncology research company Sapphire Biotech

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Axim Biotechnologies to acquire oncology research company Sapphire Biotech

Axim Biotechnologies Inc. signed a binding term sheet to acquire Sapphire Biotech Inc., an oncology research and development company.

Sapphire develops proprietary therapies for inhibiting growth and spread of cancer. The company is also developing diagnostics for early cancer detection, response to treatment and recurrence monitoring.

As part of the agreement, San Diego-based Axim Biotechnologies will acquire all of Sapphire's outstanding capital and assume all its outstanding debt.

The parties plan to enter into a definitive deal by Feb. 28.

Axim will gain Sapphire's portfolio of technologies through the deal, as well as the ability to develop new proprietary molecules, the company said in a filing.

Axim develops and produces cannabinoid-based pharmaceutical and nutraceutical products.